What is Iovance Biotherapeutics, Inc.'s exchange offer (note 12)?

Iovance Biotherapeutics, Inc. (IOVA) reported exchange offer (note 12) of $1K in Q1 2025.

What does exchange offer (note 12) mean?

Represents the non-cash impact of converting debt or other financial instruments into common equity. This activity alters the company's capital structure by reducing liabilities and increasing share count. It is a significant event for investors to monitor regarding potential dilution and balance sheet deleveraging.

Iovance Biotherapeutics, Inc. IOVA Exchange Offer (Note 12)

Exchange Offer (Note 12) at other companies

MacerichMAC

$5.23M+4,335%

Oruka Therapeutics, Inc.ORKA

$52.83M—

Quantum Computing Inc.QUBT

$1.02M+687,316%

Iovance Biotherapeutics, Inc.IOVA

$1K—

ServiceTitan, Inc.TTAN

$348.97K—

Sionna Therapeutics, Inc. Common StockSION

$0-100%

Other financials

Income statement

See full

Revenue$71.4M+44.8%

Gross profit$28.9M+338%

Operating income-$81.0M+33.1%

Net income-$79.0M+32.0%

EPS (diluted)-$0.19+47.2%

Balance sheet

See full

Cash & equivalents$196.5M+14.5%

Total debt$46.8M-11.3%

Total equity$721.8M-6.0%

Total assets$925.7M-4.2%

Cash flow

See full

Operating cash flow-$72.1M+30.5%

CapEx$6.6M+6.4%

Free cash flow-$78.7M+28.4%

Valuation

See full

Market cap$1.98B+32.4%

Enterprise value$1.83B+33.2%

P/S6.9×-0.1×

Profitability

See full

Gross margin36.7%+4.1pp

Operating margin-127.2%-31.0pp

Net margin-123.9%-28.4pp

FCF margin-106.8%-27.5pp

Returns & leverage

See full

Return on equity-47.5%-3.7pp

Debt / equity0.1×0.0×

Current ratio3.6×-0.6×

Where this comes from

Reported directly by Iovance Biotherapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ConversionOfStockAmountConverted1.

The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Iovance Biotherapeutics, Inc.'s exchange offer (note 12).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Iovance Biotherapeutics, Inc.'s exchange offer (note 12)?: Iovance Biotherapeutics, Inc. (IOVA) reported exchange offer (note 12) of $1K in Q1 2025.
What does exchange offer (note 12) mean?: Represents the non-cash impact of converting debt or other financial instruments into common equity. This activity alters the company's capital structure by reducing liabilities and increasing share count. It is a significant event for investors to monitor regarding potential dilution and balance sheet deleveraging.